Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Impact of Fruit Etiolation on Quality of Seeds in Tobacco.
Farci D, Haniewicz P, Cocco E, De Agostini A, Cortis P, Kusaka M, Loi MC, Piano D. Farci D, et al. Among authors: cocco e. Front Plant Sci. 2020 Oct 8;11:563971. doi: 10.3389/fpls.2020.563971. eCollection 2020. Front Plant Sci. 2020. PMID: 33133114 Free PMC article.
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: cocco e. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F; Italian MS Register Study Group. Chisari CG, et al. Among authors: cocco e. Neurotherapeutics. 2024 May 7:e00363. doi: 10.1016/j.neurot.2024.e00363. Online ahead of print. Neurotherapeutics. 2024. PMID: 38714462
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, Gjyzari M, Cheung T, Zhang Y, Simpkins C, Zhou W, Kulick A, Zhao P, Wei M, Shivashankar P, Prioleau T, Razavi P, Koche R, Rebecca VW, de Stanchina E, Castel P, Chan HM, Scaltriti M, Cocco E, Ji H, Luo M, Toska E. Blawski R, et al. Among authors: cocco e. Cell Rep. 2024 May 2;43(5):114174. doi: 10.1016/j.celrep.2024.114174. Online ahead of print. Cell Rep. 2024. PMID: 38700982 Free article.
453 results